{"prompt": "['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 14 of 92', 'CR845-CLIN3102', 'Period will be analyzed follow a similar mehtodology to the one', 'employed in the primary analysis of the primary endpoint.', 'Hypothesis Testing Strategy', 'Testing of the primary efficacy endpoint will be 2-sided and conducted', 'at the 5% error level. The study will be considered positive if the null', 'hypothesis of no treatment difference in the primary efficacy analysis', 'of the primary endpoint (proportion of patients with a 3-point', 'improvement from baseline at Week 12 of the Double-blind Treatment', 'Period with respect to the Worst Itching Intensity NRS) is rejected in', 'favor of the alternative that patients randomized to CR845 experience', 'significantly less itching compared to patients randomized to placebo.', 'To protect the Type 1 error, a gate-keeping strategy will be', 'implemented. Although the p-values corresponding to the hypothesis', 'testing of the secondary variables will be reported, they will only be', 'considered inferential if the primary analysis is statistically significant.', 'Testing of the secondary efficacy endpoints will be performed', 'sequentially at a 2-sided 5% error level. The difference between', 'CR845 0.5 mcg/kg and placebo with respect to the 5-D Itch total score', 'will be tested first. If results are statistically significant in favor of', 'CR845, testing with respect to the Skindex-10 total score will proceed', 'and be inferential. The proportion of patients achieving >4-point', 'improvement from baseline with respect to the weekly mean of the', 'daily 24-hour Worst Itching Intensity NRS at Week 12 of the Double-', 'blind Treatment Period will be tested only if the results of Skindex-1(', 'total score are statistically significant in favor of CR845.', 'Details and methods of analysis are found in Section 8.0 and will be', 'described further in the statistical analysis plan.', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 16 of 95']['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 15 of 92', 'CR845-CLIN3102', '2.0', 'Table of Contents', '1.0 Protocol Synopsis', '4', '2.0 Table of Contents', '15', '3.0 List of Abbreviations', '20', '4.0 Introduction', '21', '4.1', 'Background and Rationale', '21', '4.2', 'Clinical Experience', '22', '4.2.1', 'Overall Exposure', '22', '4.2.2', 'Safety in Hemodialysis Patients', '22', '4.2.3', 'Efficacy of CR845 in Hemodialysis Patients with Uremic Pruritus', '23', '4.2.4', 'Pharmacokinetics in Hemodialysis Patients', '24', '4.3', 'Summary of Potential Risks and Benefits', '25', '5.0 Objectives', '26', '6.0 Investigational Plan', '27', '6.1', 'Overall Study Design and Plan: Description', '27', '6.1.1', 'Double-blind Phase', '27', '6.1.1.1', 'Screening Visit', '27', '6.1.1.2', 'Run-in Period', '27', '6.1.1.3', 'Double-blind Treatment Period', '28', '6.1.1.4', 'Double-blind Discontinuation Period', '29', '6.1.2', 'Open-label Extension Phase', '30', '6.2', 'Selection of Study Population', '32', '6.2.1', 'Inclusion Criteria', '32', '6.2.2', 'Exclusion Criteria', '33', '6.3', 'Removal of Patients from Therapy or Assessment', '34', '6.3.1', 'Discontinuation of Individual Patients', '34', '6.3.2', 'Discontinuation or Suspension of Entire Study', '35', '6.4', 'Treatments', '36', '6.4.1', 'Treatments Administered', '36', '6.4.2', 'Identity of Investigational Product(s)', '36', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 17 of 95']\n\n###\n\n", "completion": "END"}